Cargando…
Intratumoral nanobody–IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice
Confining cytokine exposure to the tumors would greatly enhance cancer immunotherapy safety and efficacy. Immunocytokines, cytokines fused to tumor-targeting antibodies, have been developed with this intention, but without significant clinical success to date. A critical limitation is uptake by rece...
Autores principales: | Lutz, Emi A, Jailkhani, Noor, Momin, Noor, Huang, Ying, Sheen, Allison, Kang, Byong H, Wittrup, K Dane, Hynes, Richard O |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802395/ https://www.ncbi.nlm.nih.gov/pubmed/36712341 http://dx.doi.org/10.1093/pnasnexus/pgac244 |
Ejemplares similares
-
Maximizing response to intratumoral immunotherapy in mice by tuning local retention
por: Momin, Noor, et al.
Publicado: (2022) -
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies
por: Lutz, Emi A., et al.
Publicado: (2022) -
Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
por: Jailkhani, Noor, et al.
Publicado: (2023) -
Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice
por: Kang, Byong H., et al.
Publicado: (2021) -
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2
por: Horton, Brendan L., et al.
Publicado: (2023)